Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nanobiotix, an emerging nanomedicine company focused on cancer therapy, has announced that the European Patent Office has issued new patent to the company related to its novel activable particles that can be used in the health sector.
Subscribe to our email newsletter
According to the company, the patent protects composite particles that can generate free radicals or heat when excited by X-rays, and to the uses thereof in health, particularly human.
The inventive particles comprise an inorganic-based, and optionally organic-based, nucleus and can be activated in vivo, in order to label or alter cells, tissues or organs. The patent protection also relates to methods for the production of said particles, and to pharmaceutical or diagnostic compositions containing same, the company said.
Laurent Levy, president and CEO of Nanobiotix, said: “We are extremely pleased that our platform technology, nanoXray, is now patent-protected throughout the EU. We are hopeful that we will soon receive similar patent protection in the US as well.
“NanoXray is designed to allow the precise destruction of cancer cells via the controlled application of an outside-the-body energy source – a standard X-ray. Of course, protecting this intellectual property is key to long-term commercial success.”